Tirtha Chakraborty
Directeur Technique/Scientifique/R&D chez VOR BIOPHARMA INC.
Fortune : 304 696 $ au 30/04/2024
Profil
Tirtha Chakraborty is currently working as an Advisor at Specific Biologics, Inc. since 2023 and as the Chief Scientific Officer at Vor Biopharma, Inc. since 2020.
Previously, Tirtha worked as the Executive Director & Head-Hematology at CRISPR Therapeutics AG from 2015 to 2018 and as the Vice President-Cell Therapy Research at Sana Biotechnology, Inc. from 2018 to 2019.
Tirtha holds a doctorate degree from Tata Institute of Fundamental Research.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VOR BIOPHARMA, INC.
0,26% | 06/05/2024 | 179 233 ( 0,26% ) | 304 696 $ | 30/04/2024 |
Postes actifs de Tirtha Chakraborty
| Sociétés | Poste | Début |
|---|---|---|
| VOR BIOPHARMA INC. | Directeur Technique/Scientifique/R&D | 01/11/2020 |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Consultant / Advisor | 24/07/2023 |
Anciens postes connus de Tirtha Chakraborty
| Sociétés | Poste | Fin |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 01/10/2019 |
| CRISPR THERAPEUTICS AG | Directeur/Membre du Conseil | 01/10/2018 |
Formation de Tirtha Chakraborty
| Tata Institute of Fundamental Research | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| VOR BIOPHARMA INC. | Health Technology |
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| CRISPR THERAPEUTICS AG | Health Technology |
| Entreprise privées | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
